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Background: Pancreatic insufficiency and a diminished bile acid pool cause malabsorption of important essential nutrients and other dietary
components in cystic fibrosis (CF). Of particular significance is the malabsorption of fat-soluble antioxidants such as carotenoids, tocopherols
and coenzyme Q10 (CoQ10). Despite supplementation, CF patients are often deficient in these compounds, resulting in increased oxidative
stress, which may contribute to adverse health effects. This pilot study was designed to evaluate the safety of a novel micellar formulation
(CF-1) of fat-soluble nutrients and antioxidants and to determine its efficacy in improving plasma levels of these compounds and reducing
inflammatory markers in induced sputum.
Methods: Ten CF subjects, ages 8 to 45 years old, were given orally 10 ml of the CF-1 formulation daily for 56 days after a 21-day washout
period in which subjects stopped supplemental vitamin use except for a standard multivitamin. Plasma obtained at −3, 0 (baseline), 1, 2, 4,
and 8 weeks was assayed for β-carotene, γ-tocopherol, retinol, and CoQ10 as well as for safety parameters (comprehensive metabolic panel
and complete blood count). In addition, pulmonary function was measured and induced sputum was assayed for markers of inflammation and
quantitative bacterial counts both prior and during dosing.
Results: No serious adverse effects, laboratory abnormalities or elevated nutrient levels (above normal) were identified as related to CF-1.
Supplementation with CF-1 significantly increased β-carotene levels at all dosing time points when compared to screening and baseline. In
addition, γ-tocopherol and CoQ10 significantly increased from baseline in all subjects. Induced sputum myeloperoxidase significantly
decreased and there was a trend toward decreases in PMN elastase and total cell counts with CF-1. There was a significant inverse correlation
between the antioxidant levels and induced sputum changes in IL-8 and total neutrophils. Lung function and sputum bacterial counts were
unchanged.
Conclusion: The novel CF-1 formulation safely and effectively increased plasma levels of important fat-soluble nutrients and antioxidants.
In addition, improvements in antioxidant plasma levels were associated with reductions in airway inflammation in CF patients.
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Cystic fibrosis (CF) interferes with intestinal digestion and
absorption of nutrients and other dietary components.
Increased viscosity of pancreatic secretions causes obstruc-
tion of pancreatic ducts, leading ultimately to destruction and
fibrosis of the exocrine pancreas in 85% of the CF patientsed by Elsevier B.V. All rights reserved.
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enzymes causes steatorrhea and malabsorption of fat-soluble
vitamins. Absorption of fat-soluble compounds is further
impaired by a diminished bile acid pool due to increased fecal
excretion of bile and diminished bile secretion caused by CF-
associated liver disease in many CF patients [1,2]. Pancreatic
enzyme replacement therapy frequently fails to completely
correct malabsorption of lipids because of incomplete
intraluminal solubilization and/or reduced mucosal uptake
of lipids [3]. This malabsorption often precludes normaliza-
tion of plasma fat-soluble nutrients and antioxidants such
as β-carotene, tocopherols (vitamin E) and coenzyme Q10
(CoQ10) with standard nutritional supplements.
This impairment in absorption frequently leads to mal-
nutrition and deficiency of fat-soluble vitamins and antiox-
idants. Feranchak and colleagues demonstrated that
biochemical deficiency of one or more fat-soluble vitamins
was present in 45.8% (44 of 96) of patients at diagnosis of CF
between ages 4 and 8 weeks [4]. Despite supplementation
with ADEK® or other multivitamins, persistent deficiency of
either vitamin A (11.1%), vitamin D (12.5%), or vitamin E
(57.1%) was common. Furthermore, of those with initial
normal vitamin status, deficiency developed subsequently in
4.5% for vitamin A, 14.4% for vitamin D, and 11.8% for
vitamin E. Recent studies suggest that other fat-soluble
antioxidants such as CoQ10, β-carotene and γ-tocopherol are
substantially lower in CF patients than normal controls [5–9].
Chronic inflammation occurs in CF due to chronic
respiratory infections and is characterized by increased pro-
duction of pro-inflammatory cytokines and inflammatory
mediators [10]. Chronic inflammation causes increased
free radical production and, in combination with low levels
of antioxidants, increases oxidative stress in CF patients.
Oxidative stress in CF patients is evidenced by major indi-
cators including reduced oxidative resistance of low density
lipoprotein and fatty acids, increased production of mal-
ondialdehyde and thiobarbituric acid reacting substances and
hemolysis [11–14]. Increased oxidative stress has been
associated with decreased pulmonary function in CF. Brown
and colleagues demonstrated a correlation between oxidative
stress as measured by plasma malondialdehyde and pulmo-
nary function in 34 patients with CF [15]. Furthermore,
they showed that decreased plasma antioxidant status (as
measured by α-tocopherol, ascorbic acid and sulphydryl
proteins) is correlated with decreased pulmonary function.
Others have suggested that antioxidant supplementation
could potentially improve pulmonary function in CF
patients. In a study of 46 CF patients randomized to low or
high dose β-carotene supplementation, Wood and colleagues
reported that high dose supplementation improved forced
vital capacity [16]. Increases in selenium also correlated with
improved forced expiratory volume in one second (FEV1).
Finally, in a placebo-controlled clinical trial of 24 CF
patients, Renner and colleagues showed that high dose
antioxidant supplementation reduced the duration of antibi-
otic treatment from 14.5 to 9.8 days over 24 weeks [17].We conducted this pilot study in CF patients to begin
to evaluate the safety and efficacy of a highly bioavail-
able antioxidant-rich formulation supplying β-carotene, γ-
tocopherol, and CoQ10. This formulation utilizes micelle-
like particles in order to improve solubilization and intestinal
absorption and increase plasma levels of these compounds.
Plasma levels of these compounds were compared with
baseline values on standard multivitamin supplements used
in CF patients. Furthermore, the effects of this formulation
on measures of airway inflammation were explored by
collecting induced sputum prior to and during dosing.
2. Methods
CF subjects ages 8 to 45 years old, weighing more than
30 kg, with a clinical requirement for pancreatic enzymes
and a predicted FEV1N35%, were recruited from the
University of Colorado CF Center through clinic visits or
phone calls. The diagnosis of CF was confirmed with either
an elevated sweat chloride (N60 meq/l), or presence of two
disease-causing mutations in the CFTR gene and one or
more clinical features consistent with CF. Screening criteria
included that subjects had to have either a documented serum
β-carotene below 0.04 μg/ml when measured or have had no
prior measurement performed. Subjects were required to
have stable pulmonary disease as defined by both clinical
impression and no hospitalizations in the 60 days prior to
screening. Subjects were excluded if they had significant
liver disease as defined by clinical findings of portal
hypertension or cirrhosis or AST, ALT, or GGTN2x the
upper limit of normal. Subjects were also excluded if they
had diabetes mellitus requiring insulin therapy, significant
anemia (hemoglobin b9 gm/dl), were pregnant or lactating,
had oral supplementation with β-carotene or CoQ10 in
the 4 months prior to the study (other than in ADEK®,
SourceCF® or VITAMAX®), or had participated in another
interventional clinical trial within the 30 days prior to the
screening visit.
Subjects that met screening criteria and signed informed
consent at the screening visit had a physical examination,
fasting blood drawn for vitamins and nutrient levels, com-
plete blood count (CBC), comprehensive metabolic panel
(CMP), serum pregnancy test for females of childbearing
years and spirometry. Subjects were instructed to discontinue
any nutritional supplement except for a non-CF standard
multivitamin and were scheduled to return for a dosing visit
in 3 weeks.
At the dosing visit an abbreviated physical examination
was conducted, blood was obtained again for vitamins and
nutrient levels, CBC, and CMP. Spirometry was repeated
and sputum was induced and collected for evaluation of
inflammatory mediators. Subjects were given a two month
supply of the antioxidant formulation and instructed to ingest
a dose of 10 ml along with their current dose of pancreatic
enzymes and a standard multivitamin with breakfast each
day. The composition of CF-1, produced under cGMP at
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Table 1.
Subsequent visits at 1, 2, 4, and 8 weeks included repeat
complete evaluation except for spirometry and induced
sputum which were obtained at either week 4 or 8.
The study was approved by the Colorado Multiple
Institutional Review Board and the Pediatric Clinical
Translational Research Center (CTRC; formerly GCRC)
Scientific Advisory Committee. Informed written consent
was obtained from the subject and their parent or guardian
(if b18 years old). A Data and Safety Monitoring Board
(DSMB) was established to monitor the study.
2.1. Sample collection
2.1.1. Plasma
Whole blood was obtained for routine CBC and chem-
istries in the hospital laboratory. Additional blood was col-
lected into EDTA tubes and centrifuged at 3000 rpm for
5 min. Specimens were protected from light and the plasma
was removed and frozen at −70 °C.
2.1.2. Sputum induction and processing
Sputum was induced by having the subject inhale 3%
hypertonic saline for six 2-minute sessions, as previously
described [18]. At each 2-minute interval, subjects were
instructed to expectorate sputum into one of two containers
(one for microbiology and another for inflammatory
markers). The sputum specimens were then transported on
ice to the laboratories for processing within 20 min. To
measure bacterial density (sputum bacterial colony counts,
cfu/ml), one container was brought to the Microbiology
Laboratory where quantitative microbiology was performed
according to a consensus conference on CF microbiology
[19]. To determine inflammatory markers in sputum, the
second sputum aliquot was processed as previously
described [18]. Briefly, after weighing the sputum sample,
three times the volume of sterile 0.1% dithiothreitol (DTT)
(10% Sputolysin; Calbiochem-Novabiochem Corp., San
Diego, CA) and four times the volume of phosphate-
buffered saline (Dubelcco's; Gibco BRL, Grand Island, NY)
were added to the specimen. The sample was then incubated
in a shaking water bath at 37 °C for a total of 15 min and
gently mixed using a transfer pipette at 5-minute intervals to
ensure complete homogenization. Cytologic examinationTable 1
CF-1 formulation
Compound Amount (10 ml)
Beta-carotene 30 mg
Alpha-tocopherol 200 IU
Gamma-tocopherol 94 mg
Other tocopherols 31 mg
Coenzyme Q10 30 mg
Vitamin D3 400 IU
Vitamin K1 300 mcgwas performed from an aliquot of homogenized sputum to
yield sputum total neutrophil counts. The number of
squamous cells were subtracted from the total cell counts
to provide the absolute white cell counts. Therefore, total
sputum neutrophil counts represented a percentage of the
absolute white cell count (exclusive of squamous cells) and
were expressed as 103 cells/ml. Only samples that weigh
greater than 0.5 g and have less than 80% squamous cells
were considered adequate and included for further analysis.
The remaining homogenized sputum samples were vigor-
ously centrifuged and the supernatants were treated with
protease inhibitors, phenylmethylsulfonylfluoride (PMSF)
and EDTA (each from Sigma Diagnostics, St. Louis, MO), in
order to minimize proteolytic activity. The samples were
frozen at −70 °C for later analysis of inflammatory markers.
2.2. Assays
2.2.1. Vitamins and antioxidants
Plasma was assayed for α- and γ-tocopherol, retinol, β-
carotene and CoQ10 at the University of Colorado Pediatric
CTRC Core Laboratory using a validated HPLC method
[20]. 25-Hydroxyvitamin D in plasma was measured with
the use of an FDA approved RIA kit from DiaSorin
(Stillwater, MN).
2.2.2. CBC and chemistries
Both CBC and clinical chemistries were completed in the
main clinical laboratory at The Children Hospital. CBC's
were conducted with the use of a Beckman Coulter LH750
Hematology Analyzer. Clinical chemistries were conducted
with the use a Dade-Behring Dimension RXL Chemistry
Analyzer.
2.2.3. Inflammatory markers
Induced sputum inflammatory markers were analyzed at
the CTRC Core Laboratory. Myeloperoxidase (MPO) was
analyzed with a BIOXYTECH® MPO-EIA™ kit (OXIS
International Inc, Foster City, CA). PMN elastase was
analyzed with an ALPCO EIA kit (Salem, NH) and IL-8 was
analyzed using an R&D Systems EIA kit (Minneapolis,
MN).
2.2.4. Spirometry
Pulmonary function tests (PFTs) were performed using
the Sensomedics Vmax body box (VIASYS Healthcare Inc.,
Conshohocken, PA) with KOKO software. Knudsen normal
values were used to calculate the percent of predicted for each
subject. Spirometry was performed and the forced expiratory
curves were evaluated for acceptability in accordance with
American Thoracic Society recommendations.
2.3. Statistical analysis
A Sign Test was used to test the differences in the mean
antioxidants prior to (Visits 1 and 2, “pre”) and during dosing
Table 2
Patient characteristics
Enrolled (n=10)
Age (years) 16.7±4.9
Weight (kg) 50.5±11.0
Height (cm) 157±13.4
BMI (kg/m2) 20.2±2.38
FEV1 (% predicted) 86.8±22.3
Creatinine (mg/dl) 0.8±0.2
Total Bilirubin (mg/dl) 0.5±0.3
AST (units/l) 23±12
ALT (units/l) 51±9
Albumin (g/dl) 3.8±0.24
Pancreatic enzyme use 100%
FEV1, forced expiratory capacity in 1 second; AST, aspartate amino transferase;
ALT, amino alanine transferase. Values are mean±standard deviation.
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pre- and post-treatment were assessed using the signed-ranks
test. An antioxidant score was calculated by summing the
normalized changes of the antioxidants from baseline to
the time of final induced sputum (CoQ10, β-carotene, γ-
tocopherol). The change in each antioxidant was divided by
the value of that antioxidant at the time of the final induced
sputum: [CoQ10(sputum)–CoQ10(base)] /CoQ10(sputum)+
[β-carotene(sputum)–β-carotene(base)] /β-carotene(spu-
tum)+ [γ-tocopherol(sputum)–γ-tocopherol(base)] /γ-to-
copherol(sputum). Pearson correlation coefficients were
calculated to test for association. Data are presented as me-
dian or mean±standard error of the mean unless otherwise
stated. A significance level of 0.05 was considered to be
statistically significant.Table 3
Adverse events
Subject Events Severity Relationship
2 Nasal congestion Mild Not related
Increased cough
Lung sounds — crackles RLL
Abdomen slightly distended
4 Occasional headache (seasonal allergies) Mild Not related
Green nasal drainage
5 Increased cough (SAE) Moderate Not related
Shortness of breath (SAE)
6 Increased cough Mild Not related
Diminished lung sounds at bases
7 Pulmonary exacerbation (SAE) Severe Not related
10 Nauseated Mild Nausea possib
others not relBack pain
Nasal congestion
Increased cough
Increased tightness in the chest
11 Nasal congestion Mild Upset stomac
related, othersIncreased cough
Upset stomach
14 Croupy cough Mild Not related
Clear nasal drainage
SAE = severe adverse event.3. Results
Fourteen subjects with CF underwent screening from
which 10 subjects met inclusion and exclusion criteria. Data
from all 10 subjects were available for analysis of plasma
vitamin and antioxidant levels and safety parameters. Seven
subjects completed the study with both pre- and post-dosing
induced sputum and all vitamin and antioxidant time points.
Characteristics of the subjects that were enrolled in the study
are presented in Table 2.
3.1. Safety
There were 21 adverse events in 8 subjects, 3 of which
were categorized as serious adverse events (SAE) involving
2 subjects with respiratory exacerbations judged to be
unrelated to CF-1 (Table 3). One subject with an SAE had
not been dosed with CF-1 and the other had been on the
supplement for 1 week duration at the time of the adverse
event. Two events (nausea/upset stomach) could possibly be
related to the formulation. There were no notable changes in
the clinical laboratory parameters including comprehensive
clinical chemistries and complete blood counts. No vitamin
or antioxidant levels measured exceeded the laboratory's
reported normal range.
3.2. Plasma vitamins and antioxidants
β-Carotene plasma levels at screening and baseline were
near or below the limits of detection (0.03 μg/ml) in all
subjects. CF-1 significantly increased plasma β-carotene
post-dosing (pb0.01) at a supplementation level of less thanOutcome/Comments
Resolved other than nasal congestion and dose not adjusted
Resolved and dose not adjusted
Patient withdrew from the study after
one week on therapy
Resolved and dose not adjusted
Patient withdrew prior to dosing
ly related,
ated
Nausea resolved and dose not adjusted; increase cough,
tightness and nasal congestion not resolved
h possibly
not related
Upset stomach resolved and dose not adjusted;
increase cough not resolved
Resolved and dose not adjusted
Fig. 1. Box and whisker plots for serum levels of A) β-carotene (μg/ml), B) CoQ10 (μg/ml) and C) γ-Tocopherol (μg/ml) at each of the six study visits.
Supplementation with CF-1 commenced after visit 2. Whiskers denote minimum and maximum observations, box signifies 25th percentile, median, and 75th
percentile with mean represented by a ⊕. Box width varies with number of observations.
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significant change in plasma retinol in these subjects.
CoQ10 was below the lower limit of the normal range
(b0.29 μg/ml) in 40% (4 of 10) subjects at screening and 33%
(3 of 9) of subjects at baseline. Supplementation with CF-1
significantly increased mean CoQ10 plasma levels post-dosing
when compared to the pre-dosing values (pb0.01) (Fig. 1B).
CoQ10 plasma levels were normalized in all subjects following
treatment with CF-1.
γ-Tocopherol was below detectable limits (b1.0 μg/ml) in
60% (6 of 10) of subjects at screening and 78% (7 of 9)
of subjects at baseline. Supplementation with CF-1 signifi-
cantly increased mean γ-tocopherol plasma levels post-dosing
when compared to pre-dosing values (pb0.01) (Fig. 1C). γ-
Tocopherol levels were in the detectable range in all subjects
following treatment with CF-1 (no normal range established).
3.3. Induced sputum inflammatory markers
Measures of inflammatory mediators in induced sputum
were available from 7 subjects who had induced sputum
collected at visit 2 (immediately prior to dosing) and either
week 4 or 8 (Fig. 2). Myeloperoxidase decreased signifi-
cantly (p=0.04) post-dosing as compared to baseline. There
were no changes in IL-8. PMN elastase values were
approximately 35% lower and total and absolute neutrophils
were 65% lower at week 4 or 8 when compared to baseline,Fig. 2. Measures of inflammatory mediators in induced sputum collected at Pre-dos
Panel A) Total Neutrophils (103/ml), p=0.04, B) Myeloperoxidase (pg/ml) p=NSalthough statistically non-significant. Baseline plasma
CoQ10 was inversely correlated with induced sputum total
neutrophil counts (R=−0.68 p=0.04), myeloperoxidase
(R=−0.73 p=0.02) and IL-8 (R=−0.68 p=0.04) (Fig. 3).
The greatest impact on sputum inflammatory mediators was
seen when evaluating the effect of the “antioxidant score”, a
measure of the change in multiple antioxidant plasma levels
from pre-and post-dosing (Fig. 4). There was a significant
inverse correlation in the antioxidant score and changes in
IL-8 (R=−0.82, p=0.03) and total neutrophils (R=−0.80,
p=0.03). There was a trend toward a correlation between the
antioxidant score and the changes in myeloperoxidase (R=
−0.66, p=0.11).
All of the subjects had bacteria chronically cultured from
their sputum including 7 with Pseudomonas aeruginosa, 5
with Staphylococcus aureus, and 2 with Hemophilus
influenza. Antibiotic use included: azithromycin (6 subjects),
inhaled tobramycin (2 subjects), doxycycline (1 subject),
ciprofloxacin (1 subject), itraconazole (1 subject) and
trimethoprim/sulfamethoxazole (1 subject). There was no
significant change in sputum bacterial colony counts or
pulmonary function tests throughout the study.
4. Discussion
This pilot study demonstrated that this novel antioxidant
preparation, CF-1, effectively increased selected seruming visit of CF-1 antioxidant solution (visit 2) and Post-Dosing (week 4 or 8).
and C) IL-8 (pg/ml), p=NS.
Fig. 3. Inflammatory mediators at baseline are inversely correlated with CoQ10. (μg/ml), Panel A) Total neutrophils (10
3/ml) R=−0.68, p=0.04; Panel B) MPO
(pg/ml) R=−0.73, p=0.02, and Panel C) IL-8 (pg/ml), R=−0.68, p=0.04.
65K.A. Papas et al. / Journal of Cystic Fibrosis 7 (2008) 60–67antioxidant levels of CF subjects. CF-1 improved plasma
levels of β-carotene, γ-tocopherol, and CoQ10 in pancreatic
insufficient cystic fibrosis subjects. All 7 subjects who com-
pleted the study had plasma levels of these antioxidants
within the normal range at the end of the study. Most subjects
normalized plasma levels within the first week of use of this
formulation. Other than poor taste (the formulation was not
optimized for taste), few adverse events and no serious
adverse events appeared related to CF-1.
The technology in CF-1 enhances absorption and en-
ables normalization of blood levels without having to use
excessively high doses. CF-1 significantly increased plasma
β-carotene at all time points despite the large degree of
individual variability in β-carotene absorption among both
healthy individuals and those with malabsorptive problems
[13,16,17,21–23]. Studies of β-carotene supplementation in
CF patients have shown varying results, with 120 to 240 mg
of β-carotene required in one study and 2.1 mg/kg needed in
another to produce modest increases in serum levels. Doses
of 0.5–1.0 mg/kg with certain β-carotene/starch water-
dispersible formulations were necessary to achieve increased
serum levels [13,17,22,23]. Finally, Wood et al. found little
to no increase in plasma levels with supplementation [16]. It
is important to note that although β-carotene levels were
normalized in this study, there was no significant increase in
vitamin A.
Current recommended supplementation of vitamin E in
CF patients consists only of α-tocopherol. While supple-Fig. 4. Antioxidant score [(postCoQ10–preCoQ10) / preCoQ10+(postβ-carotene–preβ-ca
inversely correlated with change in inflammatory mediators after treatment with CF-1
R=−0.82, p=0.03 and Panel C) MPO (pg/ml) R=−0.66, p=0.11.mentation with high levels of α-tocopherol alone in-
creases blood levels [24,25] this strategy may result in
further imbalances in malabsorbing CF patients because such
supplementation has been shown to deplete γ-tocopherol in
the blood and tissues. In this study we evaluated vitamin E as
mixed tocopherols. The increase in the blood levels of γ-
tocopherol may be particularly important for CF patients due
to its function as a scavenger of reactive nitrogen species and
its synergistic effects with α-tocopherol [26]. Cystic fibrosis
is characterized by a neutrophil dominated airway inflam-
mation. Activated neutrophils release oxidants, proteases,
and cytokines, further sustaining and increasing the in-
flammatory response and causing direct injury to the lungs.
Improved antioxidant capacity with γ-tocopherol, especially
if present in the lungs, could potentially decrease oxidant-
mediated damage and limit the cytokine-mediated neutrophil
recruitment.
Non-antioxidant mechanisms may also mediate the
physiologic actions of antioxidants, thus explaining why
some studies have not shown a decrease in oxidative stress
parameters while showing positive correlations between
micronutrients and pulmonary function. There is growing
understanding of the non-antioxidant properties of the
tocopherols in the inhibition of PKC and NFkB and the
reduction of C-reactive protein levels, 5-lipoxygenase,
tyrosine-kinase as well as cyclooxygenase-2 [27]. β-Carotene
enhances cell-mediated and humoral immune response
through various mechanisms. Although it is not knownrotene) / preβ-carotene+(postγ-tocopherol–preγ-tocopherol) / preγ-tocopherol] is
. Panel A) Total neutrophils (103/ml) R=−0.80, p=0.03; Panel B) IL-8 (pg/ml)
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evaluation because of its antioxidant potential and the low
blood levels observed in CF patients.
Somewhat surprisingly for a pilot study of this size,
induced sputum inflammatory markers were inversely
correlated with antioxidant status. The decrease in induced
sputum myeloperoxidase and the observed decreases in
PMN elastase and total cell counts after starting CF-1
suggest a beneficial effect on lung inflammation and support
the need for further evaluation in a larger controlled clinical
trial. These inflammatory markers have been shown to
correlate with FEV1 in clinically stable CF children and may
serve as surrogate measures of lung inflammation and
ultimate pulmonary decline [28,29].
In conclusion, this pilot study shows that CF-1 can
significantly increase and normalize plasma levels of fat-
soluble antioxidants including β-carotene, γ-tocopherol, and
CoQ10 in malabsorbing CF patients. This study also suggests
a possible antioxidant-mediated improvement in selected
sputum inflammatory markers. Further research is needed to
explore the effect of fat-soluble antioxidant supplementation
in decreasing lung inflammation and potentially leading to
improved clinically relevant health outcomes in CF patients.
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